M344: Potent HDAC Inhibitor (IC50 100 nM) for Epigenetic and Cancer Research

Executive Summary: M344 (SKU A4105), provided by APExBIO, is a highly potent and cell-permeable histone deacetylase (HDAC) inhibitor with an inhibitory concentration (IC50) of 100 nM, enabling precise control of histone acetylation and gene expression in cell-based assays (APExBIO). It induces apoptosis and cell differentiation across multiple cancer cell lines, demonstrating GI50 values of 0.63–0.65 μM in MCF-7 (breast cancer), D341 MED (medulloblastoma), and CH-LA 90 (neuroblastoma) cells (Evidence). M344 enhances radiation therapy responses in human squamous carcinoma cells and regulates transcription factors such as NF-κB. It also reverses HIV-1 latency by activating LTR gene expression. The compound is insoluble in water but highly soluble in ethanol and DMSO, and is intended strictly for research use (APExBIO).

Biological Rationale

Histone acetylation status governs chromatin accessibility and transcriptional activity in eukaryotic cells. HDACs catalyze removal of acetyl groups from lysine residues on histones, leading to chromatin condensation and transcriptional repression. Aberrant HDAC activity is implicated in cancer, neurodegeneration, and viral latency. Inhibition of HDACs by small molecules like M344 increases histone acetylation, reactivates silenced genes, and modulates cell fate (Klotz 2009). Targeting HDACs is a validated strategy in oncology and infectious disease research, with emerging applications in combination regimens for solid tumors and viral reactivation protocols.

Mechanism of Action of M344

M344 is a synthetic, cell-permeable HDAC inhibitor with an IC50 value of 100 nM under standard in vitro conditions. It inhibits class I/II HDACs, leading to an accumulation of acetylated histones H3 and H4. This results in altered gene transcription, induction of pro-apoptotic factors (such as Puma), and modulation of transcription factors including NF-κB. Notably, M344 can induce apoptosis via p53-independent pathways. In HIV-1 models, M344 activates the LTR promoter, reversing latency and promoting viral gene expression. The compound is highly soluble in ethanol (≥12.88 mg/mL, ultrasonic treatment) and DMSO (≥14.75 mg/mL), but insoluble in water (APExBIO Product Page).

Evidence & Benchmarks

• Demonstrated HDAC inhibition with an IC50 of 100 nM in cell-free enzymatic assays under physiological pH and 37°C (APExBIO, product data).
• Inhibits cell proliferation in MCF-7 (breast cancer), D341 MED (medulloblastoma), and CH-LA 90 (neuroblastoma) cell lines with GI50 values of 0.63–0.65 μM after 72-hour treatment (APExBIO, product data).
• Enhances radiation-induced cytotoxicity in squamous carcinoma cell lines (SCC-35, SQ-20B) when co-administered at 1–10 μM, 24-hour pre-radiation (APExBIO, product data).
• Induces pro-apoptotic protein Puma expression via a p53-independent mechanism in cancer cell lines (M344 Mechanistic Insight).
• Activates HIV-1 LTR gene expression and reverses HIV-1 latency in latently infected cell models when used at 1–10 μM for 48–72 hours (M344 Epigenetic Mechanisms).
• Solubility: ≥12.88 mg/mL in ethanol (ultrasonic treatment), ≥14.75 mg/mL in DMSO; insoluble in water (APExBIO, product data).
• For reliable results, stock solutions should be stored at -20°C and used within days; long-term storage of solutions is not recommended (Best Practices Article).
• Experimental concentrations range from 1 μM to 100 μM, with typical treatment durations of 1–7 days (APExBIO).

Applications, Limits & Misconceptions

M344 is optimized for academic and translational research in oncology, epigenetics, and HIV-1 latency reversal. Its validated use cases include:

• Induction of cell differentiation and apoptosis in solid tumor and hematological models.
• Potentiation of radiotherapy in carcinoma cell lines.
• Activation of latent HIV-1 for reservoir studies.
• Pathway dissection involving NF-κB and p53-independent apoptosis.

This article extends and clarifies the protocol-focused scenarios described in Best Practices for Reliable HDAC Inhibitor Use by providing a mechanistic and benchmark-driven perspective. It also builds upon the translational outlook in M344: Mechanistic Insight, offering direct comparison data and strict workflow parameters. For deeper exploration of M344's tumor microenvironment effects, see M344: Next-Generation HDAC Inhibitor for Tumor Microenvironment; this article focuses on assay reproducibility and quantitative benchmarks.

Common Pitfalls or Misconceptions

• M344 is not water-soluble: Attempting to dissolve in aqueous buffers leads to precipitation and unreliable dosing.
• Not validated for in vivo use: M344 is strictly for in vitro and ex vivo research; pharmacokinetics and toxicity profiles in animals/humans are not established.
• Long-term solution storage is discouraged: Degradation and reduced potency occur if stored in solution at -20°C for extended periods (>1 week).
• Not interchangeable with all HDAC inhibitors: Potency, selectivity, and cellular effects differ; cross-comparisons require matched controls.
• Does not induce p53-dependent apoptosis exclusively: Key pro-apoptotic effects may occur independently of p53 status.

Workflow Integration & Parameters

Solubilization and Handling: Dissolve M344 in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL with ultrasonic treatment) to prepare stock solutions. Avoid water due to insolubility. Store aliquots at -20°C and minimize freeze-thaw cycles. Do not store solutions long-term; prepare fresh as needed. Ship and handle under blue ice conditions (APExBIO).

Experimental Use: Employ working concentrations between 1 μM and 100 μM, adjusting for cell density and assay duration. Typical treatments span 1–7 days. For apoptosis assays, evaluate caspase activation and annexin V staining at 24–72 hours post-treatment. For HIV-1 latency models, monitor LTR-driven gene expression by qPCR or luciferase activity after 48–72 hours of exposure.

Controls and Benchmarks: Use vehicle-only controls (DMSO or ethanol) and parallel HDAC inhibitors for comparative studies. Validate histone acetylation by western blot (anti-acetyl-H3, anti-acetyl-H4). Document GI50 and IC50 values under defined conditions for reproducibility (Best Practices Article).

Conclusion & Outlook

M344 (A4105) from APExBIO is a benchmark HDAC inhibitor with robust, quantitative performance metrics in cancer and HIV-1 latency research. Its unique profile—high potency, cell permeability, and broad mechanistic scope—supports applications in apoptosis induction, epigenetic modulation, and combination regimens. The compound’s strict handling requirements and water insolubility must be observed for reproducible results. Future directions include further comparative studies with in vivo-validated HDAC inhibitors and expansion into combinatorial epigenetic therapies. For ordering and detailed protocols, visit the M344 product page.